BACKGROUND: Clinical lipid measurements do not show the full complexity of the altered lipid metabolism associated with diabetes mellitus or cardiovascular disease. Lipidomics enables the assessment of hundreds of lipid species as potential markers for disease risk.
t ype 2 diabetes mellitus (T2DM) represents a growing health burden worldwide. 1,2 Atherothrombotic cardiovascular disease (CVD) is a major complication of T2DM and is the leading cause of death worldwide. [3] [4] [5] The increasing incidence of T2DM is placing pressure on healthcare systems. Estimating and managing the risk of CVD in those with T2DM are major concerns. To effectively target limited health resources to those patients at highest risk, new approaches to assess risk in T2DM populations are required. Different risk scores have been developed to estimate the risk of developing CVD; the Framingham risk score 6 and the United Kingdom Prospective Diabetes Study 7 score are well-established risk scores. However, the Framingham risk score has shown an underestimation of risk in T2DM populations, 8, 9 and the United Kingdom Prospective Diabetes Study score overestimated the risk of future cardiovascular events when applied to independent T2DM cohorts. 9, 10 Traditional lipid markers (total cholesterol, low-density lipoprotein [LDL] cholesterol, triglycerides, and highdensity lipoprotein cholesterol [HDL-C]), which are often used in risk scores, are altered in T2DM as a result of dysfunctional lipid and lipoprotein metabolism. However, these measures alone do not explain the complexity of the altered lipid metabolism associated with T2DM or the related cardiovascular risk. Recent development in lipidomic technologies is providing new insight into this complex area. Plasma lipid species and classes/subclasses have been found to be associated with T2DM 11 and CVD. 12 More recently, plasma lipid species have also been associated with incident cardiovascular events, 13 suggesting that these lipid species may be useful biomarkers for cardiovascular risk. However, to the best of our knowledge, no studies to date have investigated the plasma lipid profile associated with cardiovascular risk in a T2DM population.
We hypothesized that specific lipid species would be associated with future cardiovascular events in T2DM independently of existing risk factors. We further hypothesized that a combination of lipid species and conventional risk factors will provide improved prediction of future events compared with risk factors alone. We used a high-throughput mass spectrometry platform 14 for plasma lipid profiling in a case-cohort subset from the ADVANCE trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation) to identify lipid species that may predict incident cardiovascular events over a 5-year period. Our results were subsequently validated in an independent subset of patients with T2DM enrolled in the LIPID trial (Long-Term Intervention With Pravastatin in Ischemic Disease).
MethODs study Populations
The ADVANCE trial was a multicenter, randomized, doubleblind, international prospective study. In a 2×2 factorial design, the study compared the efficacy of perindopril/indapamide (2/0.625 mg for 3 months, increasing if tolerated to 4/1.25 mg) versus placebo and included an open-label evaluation of an intensive glucose-lowering regimen using modified release gliclazide, with a target glycohemoglobin of 6.5% (48 mmol/ mol) versus standard, guideline-based glycemic control on cardiovascular and renal outcomes. The study was approved by the ethics committee for each participating center, and all participants provided written informed consent 15 ; the Alfred Human Ethics Committee subsequently approved the present substudy. A total of 11 140 patients were recruited with a median of 5.0 years of follow-up. Patients were men and women who were >55 years of age and had been diagnosed with T2DM after the age of 30 years. They had a history of CVD or ≥1 additional cardiovascular risk factors. 16 Samples were collected at baseline, and then patients underwent a 6-week active treatment period during which they received the fixed combination of perindopril (2 mg) and indapamide (0.625 mg) before randomization. Of 11 140 samples, 7376 plasma samples were available from all countries involved in the ADVANCE trial except India and China. The plasma samples were stored at −80°C for a median of 8.8 years before analysis. The baseline data collected in the ADVANCE trial included clinical information, biochemical characteristics, and demographic distribution of all participants. 17 A case-cohort study design was used ( Figure 1 ). A sample (n=3154) was selected at random from the 7376 participants with available blood samples (the unenriched subcohort). This sample was then enriched with all those suffering cardiovascular events, defined as major macrovascular events, a composite of nonfatal myocardial infarction (MI), nonfatal stroke, and cardiovascular death, renal outcomes, or all-cause mortality, 15 (n=625) from the remaining 4222 participants, giving a total clinical Perspective What is new?
• We have identified plasma lipid species that are associated with future cardiovascular events (32 species) and cardiovascular death (32 species). • We have demonstrated that a small number of these plasma lipid species (4-7) can improve on current lifestyle and clinical risk factors to predict cardiovascular outcomes in individuals with type 2 diabetes mellitus who are at high risk.
What are the clinical implications?
• More discriminatory risk assessment in high-risk patients is important to guide clinical intervention and to target limited health resources. • Current biomarkers provide an incomplete view of an individual's risk for future cardiovascular events; plasma lipid species may improve current risk assessment models. • The lipid species identified in this study may represent new therapeutic targets to modify lipid metabolism and to attenuate disease progression.
ORIGINAL RESEARCH ARTICLE 1639 of 698 cardiovascular events, defined as the first occurrence of MI, stroke, or cardiovascular death, in the follow-up period and 355 cardiovascular deaths, including death after an initial nonfatal cardiovascular event ( Figure 1 ). The LIPID trial (n=9014) investigated the effect of pravastatin on death caused by coronary heart disease in patients 31 to 71 years of age with a history of MI or unstable angina and baseline cholesterol levels between 4.0 and 7.0 mmol/L and fasting triglyceride <5.0 mmol/L. Patients were randomized to 2 groups, pravastatin (40 mg/d) or placebo, 3 to 36 months after an acute coronary syndrome. From the 5991 subjects with baseline samples available, we identified 511 individuals with established T2DM. Patients with T2DM were those who identified themselves as having diabetes mellitus or who had a fasting plasma glucose ≥7 mmol/L. 18 This substudy was also approved by the Alfred Human Ethics Committee.
lipid extraction and Quantification
Lipid species were extracted from plasma samples as described previously. 19 Briefly, plasma (10 µL) was divided into aliquots in 1.5-mL Eppendorf tubes, and 100 µL of 1-butanol/methanol (1:1, vol/vol) and 5 mmol/L ammonium formate containing internal standards ( Table I in the online-only Data Supplement) were added. The mixture was vortexed for 10 seconds, sonicated for 60 minutes in a sonic water bath (18°C-24°C), and then centrifuged (16 000g, 10 minutes, 20°C). The supernatant was transferred into a 0.2-mL glass insert with Teflon insert caps for lipidomic analysis. Targeted lipidomic analysis of the ADVANCE and LIPID cohorts was performed by liquid chromatography electrospray ionization tandem mass spectrometry. Details are available in the online-only Data Supplement. Intraassay (batch) and interassay (batch) coefficients of variance (%CVs) for each lipid species, based on plasma quality control samples placed every 25 participant samples, showed median %CV values of 12% and 14%, respectively, with 90% of lipid species having intra-assay and interassay %CVs <20% and 23%, respectively ( Table II in 
statistical analysis
To facilitate interpretation of the hazard ratios, the quantitative values for each lipid species were normalized to the interquartile range for that species before association studies. Weighted Cox regression analyses were performed on the case-cohort to identify lipid classes, subclasses, and species associated with future cardiovascular events and death. Significant baseline characteristics between cardiovascular events and nonevent groups were used as covariates, in addition to treatment allocation. Significant characteristics were age, sex, body mass index (BMI), systolic blood pressure (SBP), glycohemoglobin, HDL-C, estimated glomerular filtration rate (eGFR), diabetes duration, C-reactive protein, history of macrovascular disease, history of heart failure, use of antihypertensive medication, use of antiplatelet medication, and exercise (Table 1) . Lipid-lowering medication and total cholesterol, although not significantly associated with cardiovascular outcomes, were included as covariates in separate sensitivity analyses. Continuous and categorical covariates were analyzed with Mann-Whitney U tests and χ 2 tests, respectively. The P values (2 sided) were corrected for multiple comparisons with the Benjamini-Hochberg 20 method. Statistical significance was determined as a corrected value of P<0.05. The analyses were performed in STATA version 10.1 (StataCorp LP, Inc, College Station, TX) using the STSELPRE procedure for casecohort analyses. Linear and logistic regression was used to identify associations between lipid species and cardiovascular risk factors (sex, age, BMI, and SBP) with adjustment for other risk factors and glycohemoglobin as indicated.
Principal component analysis was performed on the entire data set. 21 The stratification of the population based on sex, age, BMI, SBP, or cardiovascular outcomes across each of the principal components was determined by t tests. Correlation analysis using Pearson correlation coefficients was performed on the subset of lipid species that were associated with cardiovascular events and cardiovascular death.
Before the development of multivariable models to predict future events, a correlation minimization procedure was used on the entire lipid data set (log-transformed values) to remove highly correlated lipid species. 22 The traditional risk factors and log-transformed lipid measurements were mean centered. A 2-stage procedure was used to rank lipid species and then to build multivariable models and assess performance with the unenriched subcohort. Starting with a Cox regression base model of 14 covariates, we added up to 20 lipid species to the model in a forward selection with the aim of minimizing the Akaike information criterion. 23 This procedure was performed within a 5-fold cross-validation framework (200 repeats). Lipid species were then ranked on the basis of the average position of incorporation into these models. For comparison, lipid features were also ranked by the least absolute shrinkage and selection operator approach 24 within a 5-fold cross-validation framework (200 repeats).
Using the rank order of the 20 top lipid species (from the Akaike information criterion ranking), we created a series of models by the successive addition of lipid species to the base covariates within a 5-fold cross-validation (200 repeats). Model performance was assessed by calculating the Harrell C statistic (using the SOMERSD command in STATA), 25 continuous net reclassification indexes (NRIs), integrated discrimination improvement (IDI), and relative IDI. 26, 27 The 95% confidence intervals (CIs) for each parameter were calculated.
We sought to validate our findings in a subcohort of participants with T2DM enrolled in the LIPID trial (n=511). Weighted Cox regression and Cox regression were performed to identify the association of the top-ranked lipid species with future cardiovascular events and death in the ADVANCE and LIPID subcohorts, respectively. To facilitate the comparison, the analyses were adjusted for age, sex, BMI, SBP, HDL-C, and eGFR only. We then assessed the predictive performance of the selected lipid species by first computing the performance of the base model and then adding lipid species to the base model and calculating the change in model performance using the C statistic, continuous NRI, IDI, and relative IDI within a 5-fold cross-validation framework (200 repeats). The covariates used in the LIPID trial analyses were the continuous measures of age, BMI, cholesterol, HDL-C, triglycerides, SBP, fasting glucose, eGFR, and white blood cell count and the categorical measures of current smoking, dyspnea grade, angina grade, atrial fibrillation, sex, stroke history, hypertension history, MI history, revascularization, peripheral vascular disease, aspirin at baseline, and treatment, as have previously been used in analyses of the LIPID trial. 28 results
Baseline characteristics
Baseline characteristics that are based on the outcomes status in patients in the ADVANCE trial are shown in Table 1 . Those experiencing a cardiovascular event or death during the follow-up period were typically older, had a higher glycohemoglobin and SBP and a longer duration of T2DM, were more likely to have a history of CVD, exercised less, and had lower HDL-C and eGFR.
association of lipid classes/subclasses and species With cardiovascular Outcomes and risk Factors
Three of 22 lipid classes/subclasses were significantly associated with the risk of cardiovascular events (monohexosylceramide, dihexosylceramide, and lysoalkyl-phosphatidylcholine) and 2 subclasses were associated with the risk of cardiovascular death (monohexosylceramide and dihexosylceramide) after adjustment for covariates and correction for multiple comparisons (Figure 2 ). In addition, 32 individual lipid species were significantly associated with both future cardiovascular events and death ( Figure 3 and Table II in the online-only Data Supplement). Twenty-seven lipid species of monohexosylceramide, dihexosylceramide, trihexosylceramide, alkylphosphatidylcholine, alkenylphosphatidylcholine (containing monounsaturated fatty acids), lysoalkylphosphatidylcholine, and cholesteryl ester were directly associated with future cardiovascular events ( Figure 3 and Table II in the online-only Data Supplement). In contrast, 5 species containing polyunsaturated fatty acids (PUFAs), including phosphatidylcholine, alkenylphosphatidylcholine, and triacylglycerol, were inversely associated with future cardiovascular events ( Figure 3 and Table II in the online-only Data Supplement). The lipid signature associated with future cardiovascular death showed minimal differences compared with future cardiovascular events. Thirty-one lipid species, including ceramide, monohexosylceramide, dihexosylceramide, trihexosylceramide, sphingomyelin, alkylphosphatidylcholine, alkenylphosphatidylcholine (containing monounsaturated fatty acids), lysophosphatidylcholine, lysoalkylphosphatidylcholine, and cholesteryl ester, were directly associated with future cardiovascular death, whereas 1 species of alkenylphosphatidylcholine, PC(P-36:5), was inversely associated with future cardiovascular death ( Figure 3 and Table II in the online-only Data Supplement).
Regression analysis of those lipid species associated with cardiovascular outcomes with known risk factors Figure 2 . the association of lipid classes/subclasses with future cardiovascular outcomes.
Weighted Cox regression was performed to identify lipid classes/subclasses associated with future cardiovascular events (n=698;○) and cardiovascular death (n=355; closed diamond). Hazard ratios were adjusted for age, sex, body mass index, systolic blood pressure, glycohemoglobin, high-density lipoprotein cholesterol, estimated glomerular filtration rate, diabetes duration, C-reactive protein, history of macrovascular disease, history of heart failure, use of antihypertensive medication, use of antiplatelet medication, and exercise. The hazard ratio represents the change in outcome associated with a change in the lipid species equivalent to the interquartile range. Hazard ratios and 95% confidence intervals are shown. for CVD (sex, age, BMI, SBP) showed a strong association for ≥1 risk factors (Table III in 
sensitivity analysis
The addition of lipid-lowering medication or total cholesterol as covariates in the regression analyses described above had no effect on the hazard ratios of those lipid species associated with cardiovascular events and cardiovascular death.
Principal component and correlation analyses
The principal components PC1, PC2, and PC3 derived from the entire lipid data set explained 24.6%, 11.1%, and 8.7% of the variance. Stratification of the population on the basis of sex was observed within PC1 and PC2. Similarly, stratification of those individuals above and below the median values for age, BMI, and SBP was also observed within PC1 and PC2. In contrast, no stratification on the basis of cardiovascular outcomes was observed within PC1, PC2, or PC3 ( Figure I and Table IV in the online-only Data Supplement). Correlation analysis of the 42 lipid species associated with cardiovascular outcomes showed a complex correlation structure ( Figure 4 ).
Prediction of Future cardiovascular events and Death
The optimal model (based on the inflection points of the Akaike information criterion and C statistic values plotted against number of lipid species) for the prediction of future cardiovascular events was obtained by the addition in the online-only Data Supplement). In contrast, only 4 lipid species-the alkylphosphatidylcholines PC(O-36:1) and PC(O-36:5); a diacylglycerol, DG(16:0_22:5); and a sphingomyelin, SM(34:1)-were required to provide the optimal model for cardiovascular death (Table VI in the online-only Data Supplement). Cross-validated estimates of incremental predictive value (for future cardiovascular events) showed that the addition of 7 lipid species to a model that contained the covariate risk factors improved the C statistic from 0.680 (95% CI, 0.678-0.682) to 0.700 (95% CI, 0.698-0.702; P<0.0001), whereas the addition of 4 lipid species to a cardiovascular death model also improved the C statistic from 0.740 (95% CI, 0.738-0.742) to 0.760 (95% CI, 0.757-0.762, P<0.0001). Continuous NRIs were 0.227 (95% CI, 0.219-0.235) and 0.328 (95% CI, 0.317-0.339) for cardiovascular events and death, respectively. IDI and relative IDI also showed corresponding improvements ( Table 2 and Tables V and VI in the online-only Data Supplement). Repeating these analysis using the least absolute shrinkage and selection operator feature selection method identified 3 of the same lipid species in the top-ranked features for each model and resulted in similar but slightly inferior C statistics and NRI but slightly higher IDI values (Tables VII and VIII  in 
Validation on a subcohort of the liPiD trial
A subcohort of participants with T2DM enrolled in the LIPID trial (n=511) were used for validation. Cox regression of each lipid species used in the multivariable models for prediction of cardiovascular events and death, adjusting for age, sex, BMI, SBP, HDL-C, and eGFR, produced hazard ratios for most species similar to those found in the ADVANCE study ( Figure  II The addition of the 7 lipid species (identified in the ADVANCE cardiovascular event risk model) to the LIPID subcohort base model (21 covariates) resulted in an increase in the C statistic from 0.662 (95% CI, 0.661-0.662) to 0.684 (95% CI, 0.684-0.685; P<0.0001) and a continuous NRI of 0.297 (95% CI, 0.294-0.301). Similarly, the incorporation of the 4 lipid species (from the ADVANCE cardiovascular death risk model) to the base model to predict cardiovascular death increased the C statistic from 0.641 (95% CI, 0.637-0.645) to 0.701 (95% CI, 0.679-0.705; P<0.0001) and resulted in a continuous NRI of 0.481 (95% CI, 0.465-0.498). IDI values were also equal to or better than those observed in the ADVANCE cohort (Table 3 ).
DiscussiOn
Recent advances in liquid chromatography and mass spectrometry now enable the application of lipidomic studies in a true epidemiological setting. Here, we present the largest lipidomic study representing >1.1 million discrete lipid measurements across 3779 participants with diabetes enrolled in the ADVANCE trial. The statistical power of this large data set, together with the detailed phenotyping and clinical outcomes, has allowed us to identify associations between >40 individual lipid species with future cardiovascular outcomes. Multivariable modeling demonstrated that a small number of these lipid species can significantly improve on all other risk factors for the prediction of future cardiovascular events and death in individuals with T2DM.
sphingolipids associated With Future cardiovascular events
We observed direct associations of both monohexosylceramide and dihexosylceramide with the risk of future cardiovascular events. These glycosphingolipids are transported primarily by LDL (66%), 29 and their metabolism has previously been reported as a potential contributing factor in atherosclerosis progression. 30 Chatterjee et al 31 reported the role of oxidized LDL in the activation of lactosylceramide synthase to synthesize lactosylceramide, the major form of dihexosylceramide, in aortic smooth muscle cells. Consequently, lactosylceramide enhances the activity of nicotinamide adenine dinucleotide phosphate oxidase to generate superoxide radicals, which in turn mediate p44MAPK activation to enhance nuclear transcription factor (c-Fos) expression and to stimulate the proliferation of smooth muscle cells, thereby contributing to atherosclerosis. More recently, the inhibition of glycosphingolipid synthesis was shown to ameliorate atherosclerosis in both ApoE −/− mice and rabbits on a high-fat and high-cholesterol diet via the oxidized LDL/reactive oxygen species/c-Fos/smooth muscle cell cascade, in addition to multiple effects of lipoprotein metabolism. 32 
Phospholipids associated With Future cardiovascular events
We observed a direct association with the lysoalkylphosphatidylcholine and future cardiovascular events. In addition, a number of alkylphosphatidylcholine [PC(O)] species and alkenylphosphatidylcholine [PC(P); plasmalogen] species containing primarily saturated and monounsaturated fatty acids were directly associated ( Figure 3 and Table II in Our previous cross-sectional studies identified inverse associations between alkylphosphatidylcholine and alkenylphosphatidylcholine and phosphatidylethanolamine species in stable and unstable coronary artery disease, but we did not observe the direct associations identified in these longitudinal studies. 12 However, PC(O-34:1) has previously been reported to be significantly higher in plaque compared with plasma (a 4-fold increase), whereas the corresponding diacyl species (PC(34:1) was not different, 36 further highlighting the potential for alkylphosphatidylcholine species to accumulate in pathological conditions.
In addition to being a marker of increase flux through the plasmalogen pathway, LPC(O), also known as lysoplatelet activating factor, may have functional relevance to disease progression and risk of future cardiovascular events. LPC(O) is synthesized via the action of lipoprotein phospholipase A2 (Lp-PLA2), alternatively known as platelet-activating factor acetylhydrolyase, on PC(O) ( Figure III in the online-only Data Supplement) and is considered the major precursor of platelet activating factor, a potent proinflammatory and prothrombotic signaling lipid in oxidized LDL. 37 Reduced circulating Lp-PLA2 levels in patients with acute coronary syndrome were associated with plaque regression, 38 whereas increased levels were directly associated with the risk of coro- nary artery disease. 39 However, a recent randomized, controlled trial of an Lp-PLA2 inhibitor, darapladib, did not result in reduced cardiovascular risk despite demonstrating a 65% reduction Lp-PLA2 activity. 40 Thus, the functional roles of Lp-PLA2 and LPC(O) in coronary artery disease remain uncertain.
Fatty acids associated With Future cardiovascular events
In a population-based study, Stegemann et al 13 identified a specific cluster of triacylglycerol species with saturated and monounsaturated acyl chains as most consistently associated with CVD, and a similar set of triacylglycerols has been associated with prevalent 11 and incident 41 diabetes mellitus. We did not observe these associations in our study in patients with T2DM, which were possibly masked by the generally elevated triglycerides associated with T2DM. However, we observed a single triglyceride [TG(56:6)] that showed a novel inverse association with future cardiovascular events. We also observed 5 other lipid species from multiple classes/subclasses containing long-chain PUFAs associated with a decreased risk of future cardiovascular events and death. It has previously been reported that PUFA-containing species of phosphatidylcholine, triacylglycerol, cholesteryl ester, lysophosphatidylcholine, and lysophosphatidylethanolamine were negatively associated with T2DM. 11, 41 These observations may reflect an underlying interaction between the severity or control of T2DM in this population and cardiovascular risk. Previous studies have linked n-3 PUFA intake with traditional lipid measures and demonstrated that increased intake of n-3 PUFAs reduced triacylglycerol levels by 25% to 30%. 42 These findings may indicate an important atheroprotective effect of n-3 PUFAs, as has been extensively reviewed. 43, 44 Of the 36 lipid species that showed a direct association with cardiovascular events and death, all but one contained only saturated or monounsaturated fatty acids. The association between saturated/monounsaturated fatty acids and cardiovascular risk was also evident in the Stegemann et al 13 study. Of note, although cholesteryl esters (as a class) were not associated with cardiovascular outcomes, the saturated species CE(16:0) was directly associated with cardiovascular events in both studies, demonstrating a general agreement (at the fatty acid level) and suggesting some commonality between primary prevention and high-risk populations.
lipid species as Predictors of cardiovascular events and Death
Our initial assessment of the data structure in the AD-VANCE lipidomic data set using principal component analysis highlighted the complex nature of the data set. Although sex, age, BMI, and SBP contributed to the variance represented by the principal components, cardiovascular outcomes did not appear to be contributing to this variance, highlighting the challenge in selecting lipid species for model development. Regression analysis of the subset of lipid species associated with cardiovascular outcomes with the traditional risk factors (sex, age, BMI, and SBP) showed that the sphingolipid species, which increased risk of cardiovascular events, were inversely associated with BMI. Similarly, the same lipid species were associated with female sex, further reducing risk in the male group relative to the female group. However, the same lipid species, particularly the monohexosylceramides, were also directly associated with SBP. Other lipid species such as lysoalkylphosphatidylcholine showed strong associations with age but minimal associations with other risk factors, suggesting different biological relationships for this lipid class. These differential associations suggest that there are multiple (sometimes opposing) factors that influence lipid homeostasis and thereby cardiovascular risk. The residual risk of these lipid species, after adjustment for established risk factors, including gender, age, BMI, and SBP, likely reflects other environmental and genetic factors not currently considered in cardiovascular risk. Further analyses of this and other data sets will shed new light on this residual risk and may identify therapeutic strategies to minimize such risk. Examination of the internal correlation structure of this lipid set showed a range of correlations (positive and negative) and further highlights both the complexity of the data and the redundancy of many lipid species, an important consideration for the development of multivariable prediction models.
Cardiovascular risk scores developed for the general population have been shown to underestimate the risk of future CVD in the T2DM population. 45, 46 Scores specifically designed for T2DM perform better but also show limited performance. 47 In the ADVANCE study, the incorporation of 7 and 4 lipid species, on top of the traditional risk factors and medication, improved the prediction of cardiovascular events and death, respectively. The use of an alternative feature selection strategy (least absolute shrinkage and selection operator) identified a single lipid species [PC(O-36:1] as common to all models produced by either strategy, suggesting the robustness of certain lipid species and redundancy in other lipid species within these models.
Importantly, the addition of these same 7 and 4 lipid species identified in the modeling of the ADVANCE cohort to the base model (21 covariates) improved the risk prediction of cardiovascular events and death, respectively, in the LIPID subcohort, thus providing independent validation of these lipid species. Although the addition of the selected lipid species to prediction models gave similar improvement in model performance in both the ADVANCE and LIPID data sets, not all of the lipid species showed the same associations in the LIPID subcohort when adjusted for an identical set of covariates ( Figure II in the online-only Data Supplement). These differential associations may reflect the secondary prevention nature of the LIPID study, in which all participants had a prior history of CVD, whereas only 35% of the ADVANCE study participants had a history of macrovascular disease. We also note that not all of the lipid species incorporated into the multivariable models were independently associated with the outcome in question. We believe that this reflects the contribution they make to the overall model performance through their interaction with the other lipid species or covariates in the model. Analysis of these lipid species in other cohorts will help to resolve these questions.
In a study of lipid metabolites in a primary prevention cohort, Stegemann et al 13 showed that the addition of 6 lipid species (selected on the basis of the entire data set) to the conventional risk factors (used in the Framingham risk score) improved the C statistic and categorical NRI for cardiovascular events (incident fatal and nonfatal MI, ischemic stroke, and sudden cardiac death) by 3.74% and 14.9%, respectively. However, although the analyses were performed within a 5-fold cross-validation framework, independent validation of the lipid species was not performed. The differing performance of lipid species in terms of risk prediction in secondary prevention compared with primary prevention may relate to the many additional covariates used in the secondary prevention case-cohort analyses that are also associated with cardiovascular risk.
The observation that relatively few lipid species improved risk prediction over traditional risk factors both in a primary prevention cohort and in those with T2DM and increased baseline risk highlights the potential of individual lipid species identified by lipidomics to improve CVD risk stratification. That there was no overlap between the lipid species selected in each study may reflect metabolic differences between the cohorts related to either their clinical status (diabetes versus nondiabetes) or to the different stages of disease progression (primary versus secondary prevention) but may also be a result of the lipid species measured in each study and the statistical methods used to select the optimal lipid species for model development.
strengths and limitations of the study
This study represent the largest lipidomic study reported to date, incorporating >300 lipid species in >4000 samples from 2 independent prospective clinical trials. The use of an independent validation cohort strengthens our findings. The statistical power provided by this "big data" approach highlights the potential of lipidomic studies not only to identify new biomarkers of disease risk but also to understand the relationship of lipid metabolism with interventions, comorbidities, and clinical outcomes.
A limitation of all lipidomic studies is that the coverage of the lipidome is incomplete. In this study, we have used a targeted approach that has enabled us to measure >300 lipid species from 22 different lipid classes/ subclasses, providing a broad, but still incomplete, coverage of the lipidome. We recognize that there are many lipid species and classes/subclasses not covered in this study that may show superior predictive performance. Furthermore, the high variance associated with lipidomic measurements will lead to an underestimation of the strength of associations.
Selection of covariates for regression analysis is challenging because it is not always possible to predict interactions among covariates, lipid species, and cardiovascular events. We recognize that a large proportion of subjects (≈44%) were on lipid-lowering medication, which will influence plasma lipids in these individuals. However, lipid-lowering medication was not associated with future cardiovascular events or cardiovascular death, and when we added this as a covariate, we did not see any change in the hazard ratios for the significant lipid species. Similarly, total cholesterol was not associated with cardiovascular events and made no difference in the hazard ratios when added as a covariate (data not shown).
Although the ADVANCE study represents the largest cohort to undergo targeted lipidomic analysis to date, the case-cohort design resulted in a primarily white group, so these results may not extrapolate to all populations. We also recognize that the LIPID trial validation cohort was relatively small and that the clinical covariates were not identical to those in the ADVANCE trial. These differences notwithstanding, the covariates provided similar clinical phenotyping, and we were able to demonstrate that the same lipid species were predictive above the clinical phenotype in both cohorts.
conclusions
Multiple lipid species were independent predictors of cardiovascular events and cardiovascular death. A small number of lipid species were able to significantly improve risk stratification among those with T2DM. The associations between individual lipid species and cardiovascular risk demonstrate the statistical power resulting from lipidomic analyses of large epidemiological studies and the potential to inform on lipid metabolism in relation to chronic disease. These results further highlight the need for mechanistic studies to characterize the role of individual lipid species in disease pathogenesis. These studies also raise the potential for new intervention strat-egies (lifestyle/drug) to modify lipid metabolism and to attenuate disease progression, such as those that have recently been reported for plasmalogen modulation in a mouse model of atherosclerosis. 48 acknOWleDgMents The authors thank the investigators of the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation and the Long-Term Intervention With Pravastatin in Ischemic Diseasestudies and the patients who participated in these studies. The authors acknowledge Michelle Cinel and Ricardo Tan for technical support in the lipidomic analyses. 
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